Fate FT819 Shows Early Systemic Sclerosis Benefit
Fate Therapeutics reported that its off-the-shelf CD19 CAR T-cell therapy FT819 produced early clinical improvement in four patients with treatment-resistant systemic sclerosis within three months of administration. Patients demonstrated improvement in the modified Rodnan…
